Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Thanaporn Bussabawalai, Kittiphong Thiboonboon, Yot Teerawattananon

ABSTRACT

Background: Many patients develop tumour recurrence within a few years after undergoing surgical resection of gastrointestinal stromal tumours (GIST). Adjuvant imatinib treatment is recommended for patients with high risk of GIST recurrence as it can improve recurrence-free survival and overall survival of patients. This study aims to assess the cost-utility of adjuvant imatinib in patients with high risk of GIST recurrence after surgery compared with no adjuvant therapy in Thailand. Methods: A Markov model was developed to estimate lifetime costs and outcomes of using adjuvant imatinib treatment and other treatment alternatives if recurrence occurred compared with the current situation of no adjuvant therapy in high-risk patients after surgery. A 1-month cycle length was deployed in the model. Transition probabilities were derived from literature review. Costs were collected and calculated for the year 2014 from a societal perspective. Future costs and outcomes were discounted at 3% per year. One-way and probabilistic sensitivity analyses were conducted to assess parameter uncertainties. Results: Three years of adjuvant imatinib treatment followed by imatinib treatment and best supportive care if recurrence occurred after or during adjuvant therapy, respectively, was the best option as it produced more health outcomes (1.23 life years (LYs) and 1.16 quality-adjusted life years (QALYs)) compared to no adjuvant therapy while yielding the lowest incremental cost-effectiveness ratio (ICER) of 1,648,801 Thai Baht (THB) per QALY gained. Three years of adjuvant imatinib treatment followed by sunitinib treatment if recurrence occurred had an ICER of 2,608,264 THB per QALY gained compared to the best option, while other options were dominated. A one-way sensitivity analysis showed that the utility of patients receiving adjuvant imatinib had the greatest effect on the model, followed by the discount rate and probability of GIST recurrence. Conclusions: Adjuvant imatinib treatment improved the health benefits of patients with high risk of GIST recurrence. However, in the Thai context, it was not cost-effective at the current price. More... »

PAGES

1

References to SciGraph publications

  • 2012-06. Adjuvant treatment of GIST: patient selection and treatment strategies in NATURE REVIEWS CLINICAL ONCOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s12962-018-0169-9

    DOI

    http://dx.doi.org/10.1186/s12962-018-0169-9

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1111259693

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/30636935


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Ministry of Public Health", 
              "id": "https://www.grid.ac/institutes/grid.415836.d", 
              "name": [
                "Health Intervention and Technology Assessment Program (HITAP), Department of Health 6th floor, 6th Building, Ministry of Public Health, Tiwanon Road, Muang, 11000, Nonthaburi, Thailand"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bussabawalai", 
            "givenName": "Thanaporn", 
            "id": "sg:person.013614530215.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013614530215.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Technology Sydney", 
              "id": "https://www.grid.ac/institutes/grid.117476.2", 
              "name": [
                "Health Intervention and Technology Assessment Program (HITAP), Department of Health 6th floor, 6th Building, Ministry of Public Health, Tiwanon Road, Muang, 11000, Nonthaburi, Thailand", 
                "Centre for Health Economics Research and Evaluation, University of Technology Sydney, Haymarket, Sydney, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Thiboonboon", 
            "givenName": "Kittiphong", 
            "id": "sg:person.01026345721.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026345721.98"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ministry of Public Health", 
              "id": "https://www.grid.ac/institutes/grid.415836.d", 
              "name": [
                "Health Intervention and Technology Assessment Program (HITAP), Department of Health 6th floor, 6th Building, Ministry of Public Health, Tiwanon Road, Muang, 11000, Nonthaburi, Thailand"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Teerawattananon", 
            "givenName": "Yot", 
            "id": "sg:person.0744157567.40", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744157567.40"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1097/00000658-200001000-00008", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002575802"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/00000658-200001000-00008", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002575802"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.3111/13696998.2013.819357", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003682843"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/annonc/mdi127", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013401985"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/annonc/mds252", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014272788"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0140-6736(09)60500-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015024356"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1001/jama.2012.347", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026949683"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrclinonc.2012.74", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034885687", 
              "https://doi.org/10.1038/nrclinonc.2012.74"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/annonc/mdm410", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042508428"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.3111/13696998.2012.709204", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046017060"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1077319756", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-12", 
        "datePublishedReg": "2019-12-01", 
        "description": "Background: Many patients develop tumour recurrence within a few years after undergoing surgical resection of gastrointestinal stromal tumours (GIST). Adjuvant imatinib treatment is recommended for patients with high risk of GIST recurrence as it can improve recurrence-free survival and overall survival of patients. This study aims to assess the cost-utility of adjuvant imatinib in patients with high risk of GIST recurrence after surgery compared with no adjuvant therapy in Thailand.\nMethods: A Markov model was developed to estimate lifetime costs and outcomes of using adjuvant imatinib treatment and other treatment alternatives if recurrence occurred compared with the current situation of no adjuvant therapy in high-risk patients after surgery. A 1-month cycle length was deployed in the model. Transition probabilities were derived from literature review. Costs were collected and calculated for the year 2014 from a societal perspective. Future costs and outcomes were discounted at 3% per year. One-way and probabilistic sensitivity analyses were conducted to assess parameter uncertainties.\nResults: Three years of adjuvant imatinib treatment followed by imatinib treatment and best supportive care if recurrence occurred after or during adjuvant therapy, respectively, was the best option as it produced more health outcomes (1.23 life years (LYs) and 1.16 quality-adjusted life years (QALYs)) compared to no adjuvant therapy while yielding the lowest incremental cost-effectiveness ratio (ICER) of 1,648,801 Thai Baht (THB) per QALY gained. Three years of adjuvant imatinib treatment followed by sunitinib treatment if recurrence occurred had an ICER of 2,608,264 THB per QALY gained compared to the best option, while other options were dominated. A one-way sensitivity analysis showed that the utility of patients receiving adjuvant imatinib had the greatest effect on the model, followed by the discount rate and probability of GIST recurrence.\nConclusions: Adjuvant imatinib treatment improved the health benefits of patients with high risk of GIST recurrence. However, in the Thai context, it was not cost-effective at the current price.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1186/s12962-018-0169-9", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1032048", 
            "issn": [
              "1478-7547"
            ], 
            "name": "Cost Effectiveness and Resource Allocation", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "17"
          }
        ], 
        "name": "Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand", 
        "pagination": "1", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "3ff871e479a515ec64775d4f076a59b433eeb40c6224f70b39e5e9c2d7fa8c79"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "30636935"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "101170476"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s12962-018-0169-9"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1111259693"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s12962-018-0169-9", 
          "https://app.dimensions.ai/details/publication/pub.1111259693"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T08:40", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000319_0000000319/records_11211_00000000.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://link.springer.com/10.1186%2Fs12962-018-0169-9"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12962-018-0169-9'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12962-018-0169-9'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12962-018-0169-9'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12962-018-0169-9'


     

    This table displays all metadata directly associated to this object as RDF triples.

    116 TRIPLES      21 PREDICATES      39 URIs      21 LITERALS      9 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s12962-018-0169-9 schema:about anzsrc-for:11
    2 anzsrc-for:1112
    3 schema:author N68d3076a89454d90870114357d2f8d4b
    4 schema:citation sg:pub.10.1038/nrclinonc.2012.74
    5 https://app.dimensions.ai/details/publication/pub.1077319756
    6 https://doi.org/10.1001/jama.2012.347
    7 https://doi.org/10.1016/s0140-6736(09)60500-6
    8 https://doi.org/10.1093/annonc/mdi127
    9 https://doi.org/10.1093/annonc/mdm410
    10 https://doi.org/10.1093/annonc/mds252
    11 https://doi.org/10.1097/00000658-200001000-00008
    12 https://doi.org/10.3111/13696998.2012.709204
    13 https://doi.org/10.3111/13696998.2013.819357
    14 schema:datePublished 2019-12
    15 schema:datePublishedReg 2019-12-01
    16 schema:description Background: Many patients develop tumour recurrence within a few years after undergoing surgical resection of gastrointestinal stromal tumours (GIST). Adjuvant imatinib treatment is recommended for patients with high risk of GIST recurrence as it can improve recurrence-free survival and overall survival of patients. This study aims to assess the cost-utility of adjuvant imatinib in patients with high risk of GIST recurrence after surgery compared with no adjuvant therapy in Thailand. Methods: A Markov model was developed to estimate lifetime costs and outcomes of using adjuvant imatinib treatment and other treatment alternatives if recurrence occurred compared with the current situation of no adjuvant therapy in high-risk patients after surgery. A 1-month cycle length was deployed in the model. Transition probabilities were derived from literature review. Costs were collected and calculated for the year 2014 from a societal perspective. Future costs and outcomes were discounted at 3% per year. One-way and probabilistic sensitivity analyses were conducted to assess parameter uncertainties. Results: Three years of adjuvant imatinib treatment followed by imatinib treatment and best supportive care if recurrence occurred after or during adjuvant therapy, respectively, was the best option as it produced more health outcomes (1.23 life years (LYs) and 1.16 quality-adjusted life years (QALYs)) compared to no adjuvant therapy while yielding the lowest incremental cost-effectiveness ratio (ICER) of 1,648,801 Thai Baht (THB) per QALY gained. Three years of adjuvant imatinib treatment followed by sunitinib treatment if recurrence occurred had an ICER of 2,608,264 THB per QALY gained compared to the best option, while other options were dominated. A one-way sensitivity analysis showed that the utility of patients receiving adjuvant imatinib had the greatest effect on the model, followed by the discount rate and probability of GIST recurrence. Conclusions: Adjuvant imatinib treatment improved the health benefits of patients with high risk of GIST recurrence. However, in the Thai context, it was not cost-effective at the current price.
    17 schema:genre research_article
    18 schema:inLanguage en
    19 schema:isAccessibleForFree true
    20 schema:isPartOf N0ed9f8b7bbd64dda9379ec56e48a0183
    21 N87dbf6a3c4bb4cde85d9e208fbdea800
    22 sg:journal.1032048
    23 schema:name Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
    24 schema:pagination 1
    25 schema:productId N289686aca7c747b3b1d03c33b70b9944
    26 N661862f62c804b8d83a533a23c8d0725
    27 Nb1e87ffd75384facae636853fc333091
    28 Nd559e5ac3b1b44778e9f82f6845b70f6
    29 Ndc12067036e040fcaf785ea25518ced7
    30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111259693
    31 https://doi.org/10.1186/s12962-018-0169-9
    32 schema:sdDatePublished 2019-04-11T08:40
    33 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    34 schema:sdPublisher Na6b855fa726b4c2cb650ad9e4b748d57
    35 schema:url https://link.springer.com/10.1186%2Fs12962-018-0169-9
    36 sgo:license sg:explorer/license/
    37 sgo:sdDataset articles
    38 rdf:type schema:ScholarlyArticle
    39 N0ed9f8b7bbd64dda9379ec56e48a0183 schema:issueNumber 1
    40 rdf:type schema:PublicationIssue
    41 N289686aca7c747b3b1d03c33b70b9944 schema:name readcube_id
    42 schema:value 3ff871e479a515ec64775d4f076a59b433eeb40c6224f70b39e5e9c2d7fa8c79
    43 rdf:type schema:PropertyValue
    44 N661862f62c804b8d83a533a23c8d0725 schema:name dimensions_id
    45 schema:value pub.1111259693
    46 rdf:type schema:PropertyValue
    47 N68d3076a89454d90870114357d2f8d4b rdf:first sg:person.013614530215.34
    48 rdf:rest Nf84c7cb1bd2b486f95c34d479d570cce
    49 N87dbf6a3c4bb4cde85d9e208fbdea800 schema:volumeNumber 17
    50 rdf:type schema:PublicationVolume
    51 Na6b855fa726b4c2cb650ad9e4b748d57 schema:name Springer Nature - SN SciGraph project
    52 rdf:type schema:Organization
    53 Nb1e87ffd75384facae636853fc333091 schema:name pubmed_id
    54 schema:value 30636935
    55 rdf:type schema:PropertyValue
    56 Nd559e5ac3b1b44778e9f82f6845b70f6 schema:name doi
    57 schema:value 10.1186/s12962-018-0169-9
    58 rdf:type schema:PropertyValue
    59 Ndc12067036e040fcaf785ea25518ced7 schema:name nlm_unique_id
    60 schema:value 101170476
    61 rdf:type schema:PropertyValue
    62 Nf68ccbac85d542eb8fb90b93f10bc07c rdf:first sg:person.0744157567.40
    63 rdf:rest rdf:nil
    64 Nf84c7cb1bd2b486f95c34d479d570cce rdf:first sg:person.01026345721.98
    65 rdf:rest Nf68ccbac85d542eb8fb90b93f10bc07c
    66 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    67 schema:name Medical and Health Sciences
    68 rdf:type schema:DefinedTerm
    69 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    70 schema:name Oncology and Carcinogenesis
    71 rdf:type schema:DefinedTerm
    72 sg:journal.1032048 schema:issn 1478-7547
    73 schema:name Cost Effectiveness and Resource Allocation
    74 rdf:type schema:Periodical
    75 sg:person.01026345721.98 schema:affiliation https://www.grid.ac/institutes/grid.117476.2
    76 schema:familyName Thiboonboon
    77 schema:givenName Kittiphong
    78 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026345721.98
    79 rdf:type schema:Person
    80 sg:person.013614530215.34 schema:affiliation https://www.grid.ac/institutes/grid.415836.d
    81 schema:familyName Bussabawalai
    82 schema:givenName Thanaporn
    83 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013614530215.34
    84 rdf:type schema:Person
    85 sg:person.0744157567.40 schema:affiliation https://www.grid.ac/institutes/grid.415836.d
    86 schema:familyName Teerawattananon
    87 schema:givenName Yot
    88 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744157567.40
    89 rdf:type schema:Person
    90 sg:pub.10.1038/nrclinonc.2012.74 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034885687
    91 https://doi.org/10.1038/nrclinonc.2012.74
    92 rdf:type schema:CreativeWork
    93 https://app.dimensions.ai/details/publication/pub.1077319756 schema:CreativeWork
    94 https://doi.org/10.1001/jama.2012.347 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026949683
    95 rdf:type schema:CreativeWork
    96 https://doi.org/10.1016/s0140-6736(09)60500-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015024356
    97 rdf:type schema:CreativeWork
    98 https://doi.org/10.1093/annonc/mdi127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013401985
    99 rdf:type schema:CreativeWork
    100 https://doi.org/10.1093/annonc/mdm410 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042508428
    101 rdf:type schema:CreativeWork
    102 https://doi.org/10.1093/annonc/mds252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014272788
    103 rdf:type schema:CreativeWork
    104 https://doi.org/10.1097/00000658-200001000-00008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002575802
    105 rdf:type schema:CreativeWork
    106 https://doi.org/10.3111/13696998.2012.709204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046017060
    107 rdf:type schema:CreativeWork
    108 https://doi.org/10.3111/13696998.2013.819357 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003682843
    109 rdf:type schema:CreativeWork
    110 https://www.grid.ac/institutes/grid.117476.2 schema:alternateName University of Technology Sydney
    111 schema:name Centre for Health Economics Research and Evaluation, University of Technology Sydney, Haymarket, Sydney, Australia
    112 Health Intervention and Technology Assessment Program (HITAP), Department of Health 6th floor, 6th Building, Ministry of Public Health, Tiwanon Road, Muang, 11000, Nonthaburi, Thailand
    113 rdf:type schema:Organization
    114 https://www.grid.ac/institutes/grid.415836.d schema:alternateName Ministry of Public Health
    115 schema:name Health Intervention and Technology Assessment Program (HITAP), Department of Health 6th floor, 6th Building, Ministry of Public Health, Tiwanon Road, Muang, 11000, Nonthaburi, Thailand
    116 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...